Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

KANSAS CITY — The 2025 Winter Fancy Food Show saw more than 12,000 attendees and over 400 new product exhibits from global ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the ...

GLP-1RA weight-loss drugs provide health benefits but also pose risks, including pancreatitis, kidney problems, and ...

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...